Clinical Trial Update: AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment [NA]

View source ↗

Summary

Phase 3 DESIRABLE study evaluating denosumab (AMG 162) in participants with rheumatoid arthritis on DMARDs has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Rheumatoid Arthritis | NA | Status: COMPLETED | Results posted: 2019-12-13